Welcome to our dedicated page for Geovax Labs news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
GeoVax Labs, Inc. (GOVX) is a clinical-stage biotechnology company whose news flow centers on vaccines for infectious diseases and therapies for solid tumor cancers. Company press releases describe active clinical development of GEO-CM04S1, a next-generation COVID-19 vaccine, and Gedeptin®, a gene-directed oncolytic therapy for head and neck cancers, along with additional programs such as the GEO-MVA Mpox/Smallpox vaccine candidate and MVA-VLP-based cancer immunotherapies.
Investors following GEO-CM04S1 news will see updates on Phase 2 trials in immunocompromised patients, chronic lymphocytic leukemia (CLL) patients, and healthy adults, as well as progress on a BARDA-funded 10,000-participant Phase 2b trial comparing GEO-CM04S1 with an approved COVID-19 vaccine. News items also cover interim data reviews, such as immune response outcomes in CLL booster studies, and broader context on the role of dual-antigen MVA-based vaccines in populations with limited responses to existing vaccines.
Oncology-related news highlights Gedeptin’s completed multicenter Phase 1/2 trial in advanced head and neck cancers and plans for a Phase 2 trial in first recurrent head and neck cancer in combination with an immune checkpoint inhibitor. Additional releases discuss preclinical data and intellectual property developments for candidates like MVA-VLP-MUC1, as well as participation in conferences and panel discussions on innovative therapies for solid tumors.
GeoVax news also includes corporate and financial updates, such as registered direct offerings and private placements of common stock and warrants, government contract revenues tied to the BARDA/Project NextGen award, and quarterly financial results. For investors and observers, the GOVX news stream provides insight into clinical milestones, regulatory and funding developments, patent allowances, and corporate presentations. Bookmarking this page allows readers to monitor how GeoVax’s vaccine and immuno-oncology programs progress through clinical stages and financing events over time.
GeoVax Labs, Inc. (Nasdaq: GOVX) will report its first quarter 2022 financial results on April 27, 2022, after market close. A conference call will be hosted at 4:30 p.m. ET on the same day to discuss the results and corporate updates. Participants must pre-register for the call to receive dial-in instructions. GeoVax is focused on developing vaccines and immunotherapies for infectious diseases and cancer, with clinical trials including COVID-19 vaccines and cancer treatments. The company holds over 70 patent applications across various research areas.
The press release dated April 18, 2022, from GeoVax, Inc. was mistakenly attributed and should have been sourced to Aura FAT Projects Acquisition Corp. This correction clarifies the proper source of the information, ensuring accurate representation in the market. No financial data or significant business developments were provided in the release, indicating that this is a mere administrative update rather than a statement affecting stock performance.
Aura FAT Projects Acquisition Corp. completed its initial public offering (IPO) on April 13, 2022, raising $115 million by issuing 10 million units at $10 each, with an over-allotment of 1.5 million units. Each unit comprises one Class A ordinary share and one redeemable warrant priced at $11.50. The securities are listed on Nasdaq under the ticker symbols AFARU, AFAR, and AFARW. The company seeks to focus on emerging technology sectors in Southeast Asia and Australasia, particularly Web 3.0, blockchain, and digital financial services.
GeoVax Labs (Nasdaq: GOVX) reports significant advancements in its COVID-19 vaccine candidates. The lead candidate, GEO-CM04S1, is undergoing Phase 2 clinical trials for various patient groups. Meanwhile, the experimental GEO-CM02 vaccine showed 100% single-dose protection in animal trials, aiming for universal coronavirus immunity.
Both vaccines utilize the GV-MVA-VLP™ platform, designed to evoke broader immune responses, potentially countering emerging variants like Omicron. Upcoming expert discussions at the World Vaccine Congress highlight the continuing innovation in GeoVax’s vaccine development strategy.
GeoVax Labs (Nasdaq: GOVX) announced the issuance of Patent No. 11278607 for its immunotherapy candidate targeting the MUC1 tumor-associated antigen. This patent supports the company's vector platform, focusing on creating virus-like particles (VLPs) for cancer treatment. David Dodd, CEO, highlighted encouraging results from initial studies with MVA-VLP-MUC1 and ongoing IND-enabling animal studies. Additionally, GeoVax is advancing Gedeptin®, a treatment for head and neck cancer, currently in Phase 1/2 trials. The company's immuno-oncology pipeline includes multiple vaccine candidates.
GeoVax Labs, Inc. (GOVX) announced that its Chief Scientific Officer, Mark J. Newman, will present on March 28-31, 2022, at the Vaccine Summit Boston. The presentation focuses on the design of a universal SARS-CoV-2 vaccine, GEO-CM02, which targets evolving variants. The vaccine employs a multi-antigen strategy to enhance immune responses. GeoVax is engaged in multiple clinical trials, including GEO-CM04S1 for COVID-19 and Gedeptin® for head and neck cancer, while boasting over 70 patent applications across various infectious diseases.
GeoVax Labs (Nasdaq: GOVX) has been invited to present at Maxim Group’s 2nd Annual Virtual Growth Conference from March 28-30, 2022. CEO David Dodd will provide updates on the company's immunotherapy and vaccine research, including Phase 2 clinical programs for COVID-19 and cancer. Additionally, Chief Scientific Officer Mark Newman, PhD, will engage in a fireside chat with Maxim's Jason McCarthy, PhD, on March 30, discussing cancer vaccine developments. Investors can register for the conference and request a meeting with the CEO post-event.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced a partnership with CATO SMS for managing its two ongoing Phase 2 clinical trials of the COVID-19 vaccine candidate GEO-CM04S1. This synthetic vaccine aims to induce robust immune responses targeting both spike and nucleocapsid proteins. The first trial compares GEO-CM04S1's safety and immunogenicity to the Pfizer/BioNTech vaccine in immunocompromised patients, while the second trial evaluates GEO-CM04S1 as a booster for individuals previously vaccinated with Pfizer/BioNTech or Moderna vaccines. The company believes this dual-targeting approach may enhance protection against variants.
GeoVax Labs has initiated Phase 2 clinical trials for COH04S1, a COVID-19 investigational vaccine targeting both spike and nucleocapsid proteins. The vaccine displayed strong neutralizing antibody and T cell responses in Phase 1 trials, with no significant side effects. It is aimed at immunocompromised patients and as a booster for healthy adults. This dual-target approach may enhance protection against COVID-19 variants, providing vital T cell immunity, particularly for those unable to produce antibodies. GeoVax plans to expedite clinical advancement in collaboration with City of Hope.
The investigational COVID-19 vaccine GEO-CM04S1, licensed by GeoVax Labs Inc. (GOVX), has shown robust immune responses in Phase 1 trials, targeting both spike and nucleocapsid proteins. Currently being evaluated in Phase 2 trials for immunocompromised patients and as a booster, the vaccine demonstrated strong neutralizing antibodies against SARS-CoV-2. GeoVax sees this as a potential primary vaccine and believes it could provide better protection than current FDA-approved vaccines, particularly for those unable to produce adequate antibodies.